Literature DB >> 6202969

Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects.

B D Given, T Taylor, N K Hollenberg, G H Williams.   

Abstract

Enalapril is a converting enzyme inhibitor with a prolonged duration of action. We investigated the arterial pressure and hormonal responses to angiotensin I infusion(s) in eight normotensive human volunteers at various intervals after administration of 10 mg enalapril to assess more precisely its duration of action, particularly in relationship to angiotensin II's influence on aldosterone secretion and renal vasoconstriction. In normotensive sodium-restricted subjects, there was significant attenuation (p less than 0.025) of diastolic blood pressure response to angiotensin I infusion even as long as 28 h after administration of enalapril. This was accompanied by a significant (p less than 0.02) accumulation of angiotensin I and reduction of the angiotensin II increment in response to angiotensin I infusion. In contrast to the persistent efficacy of enalapril, as assessed by angiotensin I infusion, basal levels of angiotension II had returned to control levels by 22-24 h postdrug. Yet there was a persistent reduction of diastolic blood pressure even as long as 28 h postdrug. The persistent hypotension could not be explained on the basis of changes in other potential vasoactive factors (epinephrine, norepinephrine, bradykinin, or prostaglandin), as none of these was significantly modified by enalapril administration. In summary, enalapril in a dose of 10 mg p.o. produced a significant reduction in blood pressure in this study for up to 28 h. Unlike captopril, enalapril does not modify circulating prostaglandins and kinins. Although the level of activation of the renin-angiotensin system had returned to control values 24 h after enalapril administration, there was evidence from the angiotensin I infusions of continued blockade of the angiotensin-converting enzyme for as long as 28 h.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202969     DOI: 10.1097/00005344-198405000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system.

Authors:  C Buchwalder-Csajka; T Buclin; H R Brunner; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus.

Authors:  F Broughton Pipkin; C P Wallace
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

3.  Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.

Authors:  K A Erb; J Essig; K Breithaupt; G G Belz
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 5.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

6.  The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.

Authors:  J Essig; G G Belz; A Wellstein
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 7.  Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.

Authors:  F Moncloa; J A Sromovsky; J F Walker; R O Davies
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Authors:  T C Li Kam Wa; E D Cooke; P Turner
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

9.  The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy.

Authors:  Jordan L Rosenstock; Robert Bruno; Jin K Kim; Lev Lubarsky; Robert Schaller; Georgia Panagopoulos; Maria V DeVita; Michael F Michelis
Journal:  Int Urol Nephrol       Date:  2008-04-26       Impact factor: 2.370

10.  A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Authors:  Karina Claassen; Stefan Willmann; Thomas Eissing; Tobias Preusser; Michael Block
Journal:  Front Physiol       Date:  2013-02-08       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.